Twice-Yearly Depemokimab: A New Frontier in Severe Eosinophilic Asthma Management
- The US FDA has approved depemokimab-ulaa (Exdensur) as an add-on maintenance therapy for patients aged 12 and older with severe eosinophilic asthma.
- As the first ultra-long-acting biologic targeting IL-5, depemokimab is administered once every six months (twice yearly).
- Phase III SWIFT trials demonstrated a significant reduction in asthma exacerbations (up to 58%) compared to placebo.
- The therapy addresses a critical unmet need for patients with type 2 inflammation who remain symptomatic despite high-dose inhaled corticosteroids.
Introduction: Addressing the Burden of Severe Eosinophilic Asthma
